Pherin Article Published in the American Journal of Psychiatry
Pherin Pharmaceuticals announces the publication in the American Journal of Psychiatry of the article entitled “Effect of an Acute Intranasal Aerosol Dose of PH94B on Social and Performance Anxiety in Women With Social Anxiety Disorder."
Pherin Completes Phase 2 Clinical Trials with Aloradine IN A small Phase II study showed an antidepressant effect of PH10 after one week.
Building a Commercial Infrastructure
We have a diverse product portfolio that increases the probability for commercial success. We believe that the therapeutic advantages of our products will result in pherines becoming an important new class of approved pharmaceuticals.
Pherin Pharmaceuticals, Inc. is the leader in the development of novel compounds for intranasal spray delivery in ultra low (nanogram) dose, without the need of systemic exposure and with demonstrated excellent safety profile.
Currently we have five development programs focused in the acute treatment of neuro-psychiatric and neuroendocrine conditions.
Unique Nanodose Pharmaceuticals
Pherin Pharmaceuticals, Inc. is a clinical stage specialty drug development company that has developed a family of leading and innovative proprietary compounds called pherines for the acute treatment of neuropsychiatric and neuroendocrine conditions.
Pherin Pharmaceuticals lead program Aloradine IN (PH94B nasal spray) is being developed for the acute treatment of Social Anxiety Disorder and has regulatory process ongoing in the USA.
Liebowitz MR, Salmán E, Rosenthal N, Nicolini H, Bondani A and Monti L: Evaluation of a Unique Nanogram-Dose Intranasal Aerosol for the Acute Management of the Symptoms of Social Anxiety Disorder. Boca Raton, FL: New Clinical Drug Evaluation Unit. 2011.
Freeman EW and Monti L: Evaluation of a new low dose intranasal aerosol in the treatment of clinically significant premenstrual syndrome. Boca Raton, FL: New Clinical Drug Evaluation Unit. 2007.
Rapid acute treatment of Social Anxiety Disorder: a multicenter randomized controlled with placebo clinical trial with Aloradine™ nasal spray. Clinically Significant Improvement of Social Anxiety Disorder Symptoms During a Public Speaking Challenge.